This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
by Zacks Equity Research
PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
4 Top Stocks to Buy Ahead of Earnings Release
by Zacks Equity Research
Healthcare, consumer staples and retail sectors could be ideal investments right now, keeping in mind the growing demand for their products.
Orthofix JuniOrtho Plating System Gets Regulatory Clearances
by Zacks Equity Research
Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.
Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.
Quest Diagnostics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Quest Diagnostics.
Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing
by Zacks Equity Research
Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.
Abiomed Gets FDA Nod for Data Streaming Via Impella Connect
by Zacks Equity Research
Abiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.
5 Top-Ranked Stocks Poised to Beat on Q2 Earnings This Week
by Nalak Das
We have narrowed down our search to five Zacks Rank #1 stocks slated to release earrings results this week with a positive Earnings ESP.
Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?
by Zacks Equity Research
Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.
Quest Diagnostics (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Quest Diagnostics (DGX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics (DGX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks For July 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
Masimo (MASI) Introduces Automation and Connectivity Solution
by Zacks Equity Research
Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Integra Reports Organic Sales Drop in Preliminary Q2 Results
by Zacks Equity Research
Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.
DGX vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DGX vs. USPH: Which Stock Is the Better Value Option?
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Allscripts Extends Strategic Partnership With Microsoft
by Zacks Equity Research
Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.